Teke F.Teke M.Inal A.Kaplan M.A.Kucukoner M.Aksu R.Urakci Z.2024-04-242024-04-2420151513-7368https://doi.org/10.7314/APJCP.2015.16.1.387https://hdl.handle.net/11468/23965Background: Fluorine-18 deoxyglucose positron emission tomography computed tomography (18F-FDG-PET/CT) and bone scintigraphy (BS) are widely used for the detection of bone involvement. The optimal imaging modality for the detection of bone metastases in hormone receptor positive (+) and negative (-) groups of breast cancer remains ambiguous. Materials and Methods: Sixty-two patients with breast cancer, who had undergone both 18F-FDG-PET/CT and BS, being eventually diagnosed as having bone metastases, were enrolled in this study. Results: 18F-FDG-PET/CT had higher sensitivity and specificity than BS. Our data showed that 18F-FDG-PET/CT had a sensitivity of 93.4% and a specificity of 99.4%, whiel for BS they were 84.5%, and 89.6% in the diagnosis of bone metastases. x statistics were calculated for 18F-FDGPET/CT and BS. The x-value was 0.65 between 18F-FDG-PET/CT and BS in all patients. On the other hand, the x-values were 0.70 in the hormone receptor (+) group, and 0.51 in hormone receptor (-) group. The x-values suggested excellent agreement between all patient and hormone receptor (+) groups, while the x-values suggested good agreement in the hormone receptor (-) group. Conclusions: The sensitivity and specificity for 18F-FDG-PET/CT were higher than BS in the screening of metastatic bone lesions in all patients. Similarly 18F-FDG-PET/CT had higher sensitivity and specificity in hormone receptor (+) and (-) groups.eninfo:eu-repo/semantics/openAccessBreast NeoplasmsEmission Tomography And Computed TomographyPositronRadionuclide İmagingArticle1613873912-s2.0-849242375722564038610.7314/APJCP.2015.16.1.387Q3